Harnessing oncolytic virus-mediated immunity / / topic editors: Philippe Fournier and Volker Schirrmacher.

• TeilnehmendeR: Fournier, Philippe; Schirrmacher, V
• Place / Publishing House: Switzerland : : Frontiers Media SA,, 2015
• Year of Publication: 2015
• Language: English
• Series: Frontiers Research Topics
• Physical Description: 1 online resource (110 pages) :; illustrations; digital, PDF file(s).
• Notes: Bibliographic Level Mode of Issuance: Monograph

Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic addresses various strategies how to optimize OVs anti-tumor activity.